Panbela Therapeutics, Inc., a biopharmaceutical company, filed a prospectus supplement on May 15, 2024, to update and supplement information in a previous prospectus dated December 20, 2023, with details from its quarterly report. The supplement relates to the resale of 4,260,000 shares of common stock by selling securityholders. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.4408 per share as of May 14, 2024. The supplement, which includes the attached Quarterly Report, provides updated financial data and risk factors for investors, highlighting a high degree of risk in investing in the company's securities. The Quarterly Report details a net loss of $7.1 million for the quarter ended March 31, 2024, and a decrease in cash and cash...Show More

Panbela Therapeutics, Inc., a biopharmaceutical company, filed a prospectus supplement on May 15, 2024, to update and supplement information in a previous prospectus dated December 20, 2023, with details from its quarterly report. The supplement relates to the resale of 4,260,000 shares of common stock by selling securityholders. The company's common stock is quoted on the OTCQB under the symbol 'PBLA' with a last reported sales price of $0.4408 per share as of May 14, 2024. The supplement, which includes the attached Quarterly Report, provides updated financial data and risk factors for investors, highlighting a high degree of risk in investing in the company's securities. The Quarterly Report details a net loss of $7.1 million for the quarter ended March 31, 2024, and a decrease in cash and cash equivalents from $2.578 million to $262,000. The company has incurred significant losses since its inception and continues to face liquidity challenges, with a working capital deficit of $8.7 million and a stockholders' deficit of $3.2 million. Panbela Therapeutics has been reliant on equity and debt financing to fund its operations and has recently faced delisting from Nasdaq, with its common stock now quoted on the OTCQB. The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving commercial success with its product candidates.